Elevated Platelet Count
Essential thrombocythemia with platelet count typically greater than 600,000/µL
Reactive thrombocytosis from:
iron deficiency anemia
acute blood loss
rebound from marrow suppression or immune thrombocytopenia
Platelet counts greater than 1,000,000/µL are worrisome for acute thrombotic events.
Elevated platelet count with poorly functioning platelets does not present an increased risk for thrombosis.
Commonly Encountered Situations
Reactive thrombocytosis from a variety of causes is far more common than essential thrombocythemia (a chronic myeloproliferative disorder).
Suggested Additional Lab Testing
Test that reveals any of the causes of reactive thrombocytosis previously noted are valuable.
Tests to confirm the presence of essential thrombocythemia include:
bone marrow biopsy to show an increase in the number of megakaryocytes
normal RBC mass to exclude polycythemia vera
platelet aggregation study showing a selective impaired aggregation response only to epinephrine suggests essential thrombocythemia
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Patients and Caregivers Worry About Cost of Cancer Care
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- Opioid Shortage Influences How Cancer-Related Pain Is Managed by Inpatient Palliative Care Team
- Tumor Lysis Syndrome, Renal Failure Complicate Elotuzumab Therapy for Multiple Myeloma
- How to Help Patients at the End of Life and Their Loved Ones During the Holidays
- Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials
- Disparities Seen in Goals-of-Care Discussions With Minority vs Nonminority Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|